Inflammaging Review Maps How Senescent Cells, Mitochondria and Immune Aging Drive Chronic Inflammation
A 2026 review maps the mechanisms of age-related chronic inflammation and the senolytic, metabolic and immune interventions now being tested, mostly in animals and early human trials.
Summary
This review explains inflammaging, the persistent low-grade sterile inflammation that builds with age and is linked to heart disease, neurodegeneration, metabolic disease and frailty. It describes the main drivers. Senescent cells release inflammatory signals (SASP). Damaged mitochondria release ROS and their DNA, which act as danger signals. Innate immune pathways such as NLRP3 and NF-kB become overactive, immune cells age, and inflammation fails to switch off. Most intervention evidence comes from mice and cells. There, senolytics, senomorphics, rapamycin, metformin, caloric restriction mimetics and microbiome approaches lower inflammatory signaling, and some extend lifespan in mice. According to the abstract, early human trials in frail older adults show feasibility, safety and preliminary benefit, but the supplied text is cut off before any trial data. The review says inflammaging trajectories are shaped by lifestyle, environment and evolutionary factors. This is a narrative review, not new data.
Detailed Summary
Why it matters: inflammaging is the chronic, sterile, low-grade inflammation that accompanies aging. Epidemiological studies cited in the review show that elevated IL-6, TNF and CRP predict frailty, sarcopenia, cognitive decline and cardiovascular events, independent of traditional risk factors. This review by Cossarizza (Eur J Immunol, 2026) calls inflammaging a central driver of age-related pathology. In its introduction it says inflammaging 'is supposed to be a main causal driver' of cardiovascular disease, neurodegeneration, metabolic syndrome, osteoporosis and cancer. In humans the cited evidence is predictive association. The direct causal evidence summarized comes from mouse knockout and senescent-cell clearance models.
Mechanisms: the review identifies interlocking drivers. Senescent cells secrete the SASP (IL-6, IL-1β, TNF, matrix metalloproteinases), and single-cell work shows distinct pro-inflammatory and immunomodulatory senescent subpopulations within one tissue. Dysfunctional mitochondria leak ROS and mtDNA, which act as danger signals that activate innate immune receptors. Impaired mitophagy creates a self-reinforcing cycle, reflected in plasma mtDNA rising with age. Aged macrophages and dendritic cells show NLRP3 and NF-kB hyperactivation. Thymic involution shrinks naive T-cell output, and senescent T cells secrete SASP-like factors. Old mice have reduced specialized pro-resolving mediators (resolvins, protectins, maresins, lipoxins). Combined with defective efferocytosis, this forms a feed-forward loop in which inflammation fails to terminate. COVID-19 is described as amplifying these same pathways (NF-kB, NLRP3, cGAS-STING, senescence, T-cell exhaustion).
Preclinical evidence (mice and cells): NLRP3/IL-1β knockout and senescent-cell reporter mice provide causal links between senescence, SASP and systemic inflammation. Clearing p16Ink4a senescent cells lowers cytokines, improves regeneration and delays functional decline, with pronounced effects in liver, fat and vasculature. Hepatic S6K1 deletion reduced local and systemic inflammation without removing senescent cells, suggesting inflammation can be partly separated from senescence. In murine models, caloric restriction and mimetics (resveratrol, spermidine, NAD+ boosters) attenuated inflammaging markers, decreased hypertension and extended lifespan. IL-1β blockade, PD-1/PD-L1 modulation and thymic rejuvenation expand naive T-cell pools. When these are combined with senolytics, senescent-cell clearance is enhanced, though translatability to humans 'remains to be fully evaluated.' Senolytics (dasatinib plus quercetin, fisetin, navitoclax derivatives) exploit senescent cells' pro-survival dependencies. Senomorphics (JAK/STAT inhibitors, rapamycin, metformin) dampen SASP without killing cells. Microbiome interventions and human organoid co-cultures are described as tools for modulating and dissecting the network.
Population and lifestyle context: per the abstract, inflammaging trajectories are shaped by lifestyle, environmental exposures and evolutionary factors, which supports personalized interventions. The review frames inflammaging as integrating the exposome (diet, pollutants, infections, stress, microbiome).
Caveats: this is a narrative review without systematic methods. The supplied text ends mid-way through the senolytics/senomorphics section, so later sections, including the clinical trial data, are not available here. The abstract claims reduced inflammatory markers, better physical function and improved immune responsiveness in early-phase trials in frail older adults, but no designs, sizes or effect sizes are available here. Biomarkers, long-term safety and heterogeneity across aging populations remain unresolved.
Key Findings
- Mechanism and function (mice): clearing p16Ink4a senescent cells lowered pro-inflammatory cytokines, improved tissue regeneration and delayed functional decline; tissue-specific models show pronounced effects in liver, fat and vasculature.
- Mechanism (mice): hepatic S6K1 deletion reduced local and systemic inflammation without eliminating senescent cells, partly dissociating inflammation from senescence.
- Mechanism, function and lifespan (mice): caloric restriction and mimetics (resveratrol, spermidine, NAD+ boosters) attenuated inflammaging markers, decreased hypertension and extended lifespan in murine models.
- Mechanism (mice): old mice have reduced specialized pro-resolving mediators; together with defective efferocytosis, this forms a feed-forward loop that keeps inflammation from resolving.
- Mechanism (preclinical): immune-directed therapies (IL-1β blockade, PD-1/PD-L1 modulation, thymic rejuvenation) combined with senolytics enhance senescent-cell clearance; human translatability remains to be fully evaluated.
- Human association: elevated IL-6, TNF and CRP predict frailty, sarcopenia, cognitive decline and cardiovascular events independent of traditional risk factors, and plasma mtDNA rises with age.
- Early-phase trials in frail older adults reportedly show feasibility, safety and preliminary efficacy on inflammatory markers, physical function and immune responsiveness (abstract only; supplied text ends before trial data).
Methodology
This is a narrative review in the European Journal of Immunology (2026), not a systematic review or meta-analysis. The supplied text describes no search strategy, inclusion criteria or quality grading. It synthesizes mouse knockout and senescent-cell reporter models, in vitro and organoid work, single-cell transcriptomics, human epidemiological associations and, per the abstract, early clinical studies. The supplied text is truncated mid-way through section 3.2 (senolytics/senomorphics), so later sections, including human trial design, sizes and effect sizes, could not be checked or extracted.
Study Limitations
The review is narrative and may reflect selection bias. Much of the intervention evidence is preclinical, and the review states that human translatability of immune-directed plus senolytic combinations 'remains to be fully evaluated.' The author lists biomarker development, long-term safety and heterogeneity across aging populations as open challenges. No conflicts of interest were visible in the supplied text. The supplied text is truncated in section 3.2, before the clinical trial data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
